Comprehensive Outcomes of On- and Off-Antiviral Prophylaxis in Hepatitis B Patients Undergoing Cancer Chemotherapy: A Competing Risks Analysis

被引:12
作者
An, Jihyun [1 ]
Shim, Ju Hyun [1 ]
Kim, Seon-Ok [2 ]
Choi, Jonggi [1 ]
Kim, Sang-We [3 ]
Lee, Danbi [1 ]
Kim, Kang Mo [1 ]
Lim, Young-Suk [1 ]
Lee, Han Chu [1 ]
Chung, Young-Hwa [1 ]
Lee, Yung Sang [1 ]
Suh, Dong Jin [4 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Asan Liver Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biostat & Clin Epidemiol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Vievisnamuh Hosp, Dept Internal Med, Seoul, South Korea
关键词
hepatitis B virus; chemotherapy; antiviral prophylaxis; cancer; relapse; reactivation; VIRUS HBV REACTIVATION; DNA VIRAL LOAD; CYTOTOXIC CHEMOTHERAPY; LYMPHOMA PATIENTS; LAMIVUDINE; PREVENTION; ENTECAVIR; ANTIGEN; ASSOCIATION; THERAPY;
D O I
10.1002/jmv.24512
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Although antiviral prophylaxis is essential in hepatitis B patients in the context of cancer chemotherapy, there is little evidence-based consensus regarding the appropriate prevention strategy depending on the underlying type of cancer and viral status. This retrospective study included a comprehensive cohort of 302 hepatitis B surface antigen-positive patients with various cancers undergoing chemotherapy and antiviral prophylaxis. The rates of hepatitis B virus (HBV) reactivation during antiviral therapy (>1 log(10)IU/mL increase or positive conversion of serum HBV DNA) and relapse when off antivirals ([re] appearance of HBV DNA>2,000 IU/ml with related alanine aminotransferase elevation) were evaluated, together with the associated risk factors, in a competing risks analysis where cancer death was considered as the competing event. During antiviral prophylaxis, HBV was reactivated in six patients (1.9%), who had leukemia (n = 4) or lymphoma (n = 2) and were treated with lamivudine (n = 4) or entecavir (n = 2). The incidence rate of HBV relapse in 127 off-prophylaxis patients was 21.3% during a median post-antiviral period of 11.7 months. Lymphoma, pre-prophylactic HBV DNA >= 2,000 IU/ml, and age >= 50 years were independent predictors of off-treatment HBV relapse (adjusted hazard ratios 5.25, 3.07, and 0.34, respectively; Ps<0.05). Antiviral and anticancer drugs, duration of consolidation on antiviral prophylaxis, and HBeAg positivity were not independent predictors. In conclusion, hepatitis B flare-ups are not rare in patients receiving cancer chemotherapy during and after anti-HBV prophylaxis, even when potent antivirals are used. Patients with hematopoietic or lymphoid neoplasms or high viral burdens should receive prolonged and powerful HBV prophylaxis. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:1576 / 1586
页数:11
相关论文
共 32 条
[1]   Epidemiology of hepatitis B in Europe and worldwide [J].
Alter, MJ .
JOURNAL OF HEPATOLOGY, 2003, 39 :S64-S69
[2]   The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment [J].
Chen, Chien-Hung ;
Lu, Sheng-Nan ;
Hung, Chao-Hung ;
Wang, Jing-Houng ;
Hu, Tsung-Hui ;
Changchien, Chi-Sin ;
Lee, Chuan-Mo .
JOURNAL OF HEPATOLOGY, 2014, 61 (03) :515-522
[3]   Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease [J].
Chen, Fei W. ;
Coyle, Luke ;
Jones, Brett E. ;
Pattullo, Venessa .
LIVER INTERNATIONAL, 2013, 33 (08) :1203-1210
[4]   Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation With Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg? [J].
Di Bisceglie, Adrian M. ;
Lok, Anna S. ;
Martin, Paul ;
Terrault, Norah ;
Perrillo, Robert P. ;
Hoofnagle, Jay H. .
HEPATOLOGY, 2015, 61 (02) :703-711
[5]   Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis [J].
Dong, Hua-Jie ;
Ni, Ling-Na ;
Sheng, Gui-Feng ;
Song, Hong-Lei ;
Xu, Jian-Zhong ;
Ling, Yang .
JOURNAL OF CLINICAL VIROLOGY, 2013, 57 (03) :209-214
[6]   Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports [J].
Evens, A. M. ;
Jovanovic, B. D. ;
Su, Y. -C. ;
Raisch, D. W. ;
Ganger, D. ;
Belknap, S. M. ;
Dai, M. -S. ;
Chiu, B. -C. C. ;
Fintel, B. ;
Cheng, Y. ;
Chuang, S. -S. ;
Lee, M. -Y. ;
Chen, T. -Y. ;
Lin, S. -F. ;
Kuo, C. -Y. .
ANNALS OF ONCOLOGY, 2011, 22 (05) :1170-1180
[7]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[8]  
HUANG H, 2014, JAMA, V312, P2521
[9]   Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy [J].
Hui, CK ;
Cheung, WWW ;
Au, WY ;
Lie, AKW ;
Zhang, HY ;
Yueng, YH ;
Wong, BCY ;
Leung, N ;
Kwong, YL ;
Liang, R ;
Lau, GKK .
GUT, 2005, 54 (11) :1597-1603
[10]   Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases [J].
Hwang, J. P. ;
Barbo, A. G. ;
Perrillo, R. P. .
JOURNAL OF VIRAL HEPATITIS, 2015, 22 (03) :346-352